Content deleted Content added
Graeme Bartlett (talk | contribs) added Category:Isopropyl compounds using HotCat |
Graeme Bartlett (talk | contribs) added Category:Pyrrolidines using HotCat |
||
Line 84: | Line 84: | ||
[[Category:Carbamates]] |
[[Category:Carbamates]] |
||
[[Category:Isopropyl compounds]] |
[[Category:Isopropyl compounds]] |
||
[[Category:Pyrrolidines]] |
|||
{{antiinfective-drug-stub}} |
{{antiinfective-drug-stub}} |
Latest revision as of 08:10, 11 May 2024
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C41H50N8O8 |
Molar mass | 782.899 g·mol−1 |
|
Coblopasvir is a pharmaceutical drug for the treatment of hepatitis C.[1] It is a pan-genotypic inhibitor of HCV nonstructural protein 5A.[2]
In China, it is approved for use in combination with sofosbuvir for treating naïve or interferon‐experienced adults chronically monoinfected patients with HCV of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.[2]
References[edit]
- ^ Rao H, Song G, Li G, Yang Y, Wu X, Guan Y, et al. (January 2020). "Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis". Journal of Viral Hepatitis. 27 (1): 45–51. doi:10.1111/jvh.13208. PMID 31520460.
- ^ a b Gao Y, Kong F, Li G, Li C, Zheng S, Lin J, et al. (November 2020). "Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial". Liver International. 40 (11): 2685–2693. doi:10.1111/liv.14633. PMC 7702130. PMID 33047868.